Glofitamab

Last Updated: 11/08/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 209 publications

The efficacy and safety of glofitamab combined with polatuzumab vedotin in the treatment of 9 cases of relapsed/refractory diffuse large B-cell lymphoma after failing CAR-T cell therapy

The efficacy and safety of glofitamab combined with polatuzumab vedotin in the treatment of 9 cases of relapsed/refractory diffuse large B-cell lymphoma after failing CAR-T cell therapy

Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

Published: September 07, 2026

α2,3-sialylation on human naïve T cells restrains bispecific engager-mediated anti-tumor immunity.

α2,3-sialylation on human naïve T cells restrains bispecific engager-mediated anti-tumor immunity.

Journal: bioRxiv : the preprint server for biology

Published: August 20, 2026

Glofitamab with polatuzumab vedotin in relapsed/refractory central nervous system lymphomas.

Glofitamab with polatuzumab vedotin in relapsed/refractory central nervous system lymphomas.

Journal: Blood advances

Published: August 19, 2026

Radiotherapy in Combination with CD20×CD3 Bispecific Antibodies for B-Cell Lymphoma: Biological Rationale, Current Evidence, and Open Questions.

Radiotherapy in Combination with CD20×CD3 Bispecific Antibodies for B-Cell Lymphoma: Biological Rationale, Current Evidence, and Open Questions.

Journal: Cancers

Published: July 23, 2026

Glofitamab for relapsed/refractory B-cell lymphoma: analysis of efficacy and influencing factors

Glofitamab for relapsed/refractory B-cell lymphoma: analysis of efficacy and influencing factors

Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

Published: July 06, 2026

Glofitamab for the treatment of relapsed/refractory hairy cell leukemia: a case report.

Glofitamab for the treatment of relapsed/refractory hairy cell leukemia: a case report.

Journal: Leukemia & lymphoma

Published: July 06, 2026

The Great Debate: CAR-T-Cell Therapy Versus Bispecific Antibodies in B-Cell Lymphoma.

The Great Debate: CAR-T-Cell Therapy Versus Bispecific Antibodies in B-Cell Lymphoma.

Journal: Cancers

Published: July 01, 2026

Safety evaluation of CD3×CD20 bispecific antibodies: a pharmacovigilance study using FDA adverse event reporting system.

Safety evaluation of CD3×CD20 bispecific antibodies: a pharmacovigilance study using FDA adverse event reporting system.

Journal: BMJ open

Published: June 30, 2026

Real-world outcomes of glofitamab monotherapy in heavily pretreated patients with relapsed/refractory diffuse large B-cell lymphoma: A multicenter Korean cohort.

Real-world outcomes of glofitamab monotherapy in heavily pretreated patients with relapsed/refractory diffuse large B-cell lymphoma: A multicenter Korean cohort.

Journal: Annals of hematology

Published: June 28, 2026

Immune-effector and infection-associated reporting patterns of CD20×CD3 bispecific antibodies in B-cell lymphoma: a label-anchored FAERS analysis with descriptive JADER contextualization.

Immune-effector and infection-associated reporting patterns of CD20×CD3 bispecific antibodies in B-cell lymphoma: a label-anchored FAERS analysis with descriptive JADER contextualization.

Journal: Frontiers in immunology

Published: June 26, 2026

Emerging T-Cell Engagers and Novel Immunotargets in Multiple Myeloma.

Emerging T-Cell Engagers and Novel Immunotargets in Multiple Myeloma.

Journal: Oncology (Williston Park, N.Y.)

Published: June 22, 2026

A Comprehensive Meta-Analysis of the Cardiovascular Adverse Effects of Bispecific Antibody Therapy in Hematologic Malignancies.

A Comprehensive Meta-Analysis of the Cardiovascular Adverse Effects of Bispecific Antibody Therapy in Hematologic Malignancies.

Journal: Pathophysiology : the official journal of the International Society for Pathophysiology

Published: June 12, 2026

Showing 1-12 of 209

Last Updated: 11/08/2026